Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

121. Bioidentical hormone replacement therapy for menopausal symptoms

Bioidentical hormone replacement therapy for menopausal symptoms Bioidentical hormone replacement therapy for menopausal symptoms Bioidentical hormone replacement therapy for menopausal symptoms Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bioidentical hormone replacement therapy for menopausal symptoms. Lansdale: HAYES, Inc.. Directory Publication. 2013 (...) Authors' conclusions Bioidentical hormone replacement therapy (BHRT) includes both "natural", compounded hormones obtained from compounding pharmacies and Food and Drug Administration-approved hormones that are identical to endogenous hormones. BHRT is used to treat the symptoms of menopause, including: vasomotor symptoms, urogenital symptoms, and bone loss. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Hormone Replacement Therapys

2013 Health Technology Assessment (HTA) Database.

122. Morphology of Mandibular Inferior Cortex in Panoramic Radiograph Can Help Diagnose Osteoporosis in Post Menopausal Women

Morphology of Mandibular Inferior Cortex in Panoramic Radiograph Can Help Diagnose Osteoporosis in Post Menopausal Women UTCAT2545, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Morphology of Mandibular Inferior Cortex in Panoramic Radiograph Can Help Diagnose Osteoporosis in Post Menopausal Women Clinical Question In postmenopausal women can the morphology of the mandibular inferior cortex be used as a screening (...) postmenopausal women (Group A) and 157 Post Menopausal women with histories of hysterectomy, oophorectomy, or estrogen use (Group B). Subjects had a diagnostic performances of panoramic measurements, Bone Mineral Density (BMD) at the lumber Spine (L2-L4) was measured by Dual –Energy X-ray Absorptiometry In vivo study Clinical trial Key results Dual Energy X ray Absorptiometry (DXA) of the Lumbar Spines (Bone Mineral Density) is the Gold Standard for Diagnosing Osteoporosis. Study group was categorized into 3

2013 UTHSCSA Dental School CAT Library

123. Acupuncture for menopausal hot flushes. (PubMed)

Acupuncture for menopausal hot flushes. Hot flushes are the most common menopausal vasomotor symptom. Hormone therapy (HT) has frequently been recommended for relief of hot flushes, but concerns about the health risks of HT have encouraged women to seek alternative treatments. It has been suggested that acupuncture may reduce hot flush frequency and severity.To determine whether acupuncture is effective and safe for reducing hot flushes and improving the quality of life of menopausal women (...) for Complementary and Alternative Medicine (NCCAM), BIOSIS, AMED, Acubriefs, and Acubase.Randomized controlled trials comparing any type of acupuncture to no treatment/control or other treatments for reducing menopausal hot flushes and improving the quality of life of symptomatic perimenopausal/postmenopausal women were eligible for inclusion.Sixteen studies, with 1155 women, were eligible for inclusion. Three review authors independently assessed trial eligibility and quality, and extracted data. We pooled

2013 Cochrane

124. Abnormal Uterine Bleeding in Pre-Menopausal Women

Abnormal Uterine Bleeding in Pre-Menopausal Women 404 Toggle navigation Toggle search Keyword search language Keyword search 404 Error Page/Asset Not Found The Society of Obstetricians and Gynaecologists of Canada (SOGC) {1} {1} {1}

2013 Society of Obstetricians and Gynaecologists of Canada

125. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society

Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society Menopause: The Journal of The North American Menopause Society Vol. 20, No. 9, pp. 888/902 DOI: 10.1097/gme.0b013e3182a122c2 * 2013 by The North American Menopause Society POSITION STATEMENT Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society Abstract Objective: To update and expand the previous position statement (...) of The North American Menopause Society (NAMS) on the management of symptomatic vulvovaginal atrophy (VVA) in postmenopausal women. Methods:NAMSsearchedPubMedformedicalliteratureonVVApublishedsincetheir2007positionstatement on the role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women. A panel of ac- knowledged experts in the field of genitourinary health reviewed the literature to evaluate new evidence on local estrogen as well as on other management options available

2013 The North American Menopause Society

126. Global Consensus Statement on Menopausal Hormone Therapy

Global Consensus Statement on Menopausal Hormone Therapy CLIMACTERIC 2013;16:203–204 © 2013 International Menopause Society and Elsevier Inc. DOI: 10.3109/13697137.2013.771520 This Statement is being simultaneously published in the journals Climacteric and Maturitas , on behalf of the International Menopause Society and The European Menopause and Andropause Society, respectively. Correspondence: T. J. de Villiers, MediClinic Panorama, Parow 7500, South Africa Global Consensus Statement (...) on Menopausal Hormone Therapy T. J. de Villiers , M. L. S. Gass * , C. J. Haines † , J. E. Hall ‡ , R. A. Lobo * * , D. D. Pierroz † † and M. Rees ‡ ‡ MediClinic Panorama and Department of Obstetrics and Gynecology, Stellenbosch University, Cape Town, South Africa; * Department of Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine, Cleveland, OH, USA; † Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Prince of Wales

2013 The North American Menopause Society

127. Osphena (ospemifene) - To treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause

Osphena (ospemifene) - To treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Osphena (ospemifene) Oral Tablets Company: Shionogi Inc. Application No.: 203505 Approval Date: 2/26/2013 Persons with disabilities having problems accessing the PDF files below may

2013 FDA - Drug Approval Package

128. Duavee (conjugated estrogens / bazedoxifene) - To treat moderate-to-severe hot flashes (vasomotor symptoms) associated with menopause and to prevent osteoporosis after menopause

Duavee (conjugated estrogens / bazedoxifene) - To treat moderate-to-severe hot flashes (vasomotor symptoms) associated with menopause and to prevent osteoporosis after menopause Drug Approval Package: Duavee NDA #022247 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Duavee (conjugated estrogens and bazedoxifene) Company: Wyeth Pharmaceuticals, Inc. Application No.: 022247 Approval Date: 10/3/2013 Persons with disabilities having problems accessing

2013 FDA - Drug Approval Package

129. Systematic review: Hormone therapy not recommended for chronic disease prevention in menopausal women

Systematic review: Hormone therapy not recommended for chronic disease prevention in menopausal women Hormone therapy not recommended for chronic disease prevention in menopausal women | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Hormone therapy not recommended for chronic disease prevention in menopausal women Article Text Prevention Systematic review Hormone therapy not recommended for chronic disease prevention in menopausal women Nanette K

2013 Evidence-Based Medicine (Requires free registration)

130. Efficacy of Cognitive Behavioral Therapy and Physical Exercise in Alleviating Treatment-Induced Menopausal Symptoms in Patients With Breast Cancer: Results of a Randomized, Controlled, Multicenter Trial (PubMed)

Efficacy of Cognitive Behavioral Therapy and Physical Exercise in Alleviating Treatment-Induced Menopausal Symptoms in Patients With Breast Cancer: Results of a Randomized, Controlled, Multicenter Trial The purpose of our study was to evaluate the effect of cognitive behavioral therapy (CBT), physical exercise (PE), and of these two interventions combined (CBT/PE) on menopausal symptoms (primary outcome), body image, sexual functioning, psychological well-being, and health-related quality (...) of life (secondary outcomes) in patients with breast cancer experiencing treatment-induced menopause.Patients with breast cancer reporting treatment-induced menopausal symptoms (N=422) were randomly assigned to CBT (n=109), PE (n=104), CBT/PE (n=106), or to a waiting list control group (n=103). Self-report questionnaires were completed at baseline, 12 weeks, and 6 months. Multilevel procedures were used to compare the intervention groups with the control group over time.Compared with the control group

2012 EvidenceUpdates

131. Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: U.S. Preventive Services Task Force Recommendation Statement. (PubMed)

Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: U.S. Preventive Services Task Force Recommendation Statement. Update of the 2005 U.S. Preventive Services Task Force (USPSTF) recommendation statement on hormone therapy for the prevention of chronic conditions in postmenopausal women.The USPSTF commissioned a review of the literature to update evidence about the benefits and harms of using menopausal hormone therapy to prevent chronic conditions, as well as whether (...) the benefits and harms of hormone therapy differ by population subgroups defined by age; the presence of comorbid medical conditions; and the type, dose, and method of hormonal delivery.This recommendation applies to postmenopausal women who are considering hormone therapy for the primary prevention of chronic medical conditions. It does not apply to women who are considering hormone therapy for the management of menopausal symptoms, such as hot flashes or vaginal dryness. It also does not apply to women

Full Text available with Trip Pro

2012 Annals of Internal Medicine

132. Paced Respiration for Vasomotor and Other Menopausal Symptoms: A Randomized, Controlled Trial (PubMed)

Paced Respiration for Vasomotor and Other Menopausal Symptoms: A Randomized, Controlled Trial Paced respiration has been internationally recommended for vasomotor symptom management, despite limited empirical evidence.To evaluate efficacy of a paced respiration intervention against breathing control and usual care control for vasomotor and other menopausal symptoms.A 16-week, 3-group, partially blinded, controlled trial with 2:2:1 randomization and stratification by group (breast cancer (...) , no cancer), in a Midwestern city and surrounding area.Two hundred and eighteen randomized women (96 breast cancer survivors, 122 menopausal women without cancer), recruited through community mailings and registries (29 % minority).Training, home practice support, and instructions to use the breathing at the time of each hot flash were delivered via compact disc with printed booklet (paced respiration intervention) or digital videodisc with printed booklet (fast shallow breathing control). Usual care

Full Text available with Trip Pro

2012 EvidenceUpdates

133. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial (PubMed)

Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial Hot flushes and night sweats (HFNS) affect 65-85% of women after breast cancer treatment; they are distressing, causing sleep problems and decreased quality of life. Hormone replacement therapy is often either undesirable or contraindicated. Safe, effective non-hormonal treatments are needed. We investigated whether cognitive behavioural therapy (CBT) can

Full Text available with Trip Pro

2012 EvidenceUpdates

134. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. preventive services taskforce recommendations

Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. preventive services taskforce recommendations Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

135. Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendations. (PubMed)

Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendations.

2012 Annals of Internal Medicine

136. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium

Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium Hiligsmann M, Reginster JY Record Status This is a critical abstract of an economic evaluation (...) . Bibliographic details Hiligsmann M, Reginster JY. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. PharmacoEconomics 2011; 29(10): 895-911 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Aged; Aged, 80 and over; Antibodies, Monoclonal /economics /therapeutic use; Antibodies, Monoclonal, Humanized; Belgium; Bone Density Conservation Agents /economics /therapeutic use; Cost-Benefit

Full Text available with Trip Pro

2012 NHS Economic Evaluation Database.

137. Health symptoms during midlife in relation to menopausal transition: British prospective cohort study. (PubMed)

Health symptoms during midlife in relation to menopausal transition: British prospective cohort study. To characterise symptoms experienced by women during the transition into natural menopause, to classify women into distinct symptom profiles or trajectories, and to relate these profiles to sociodemographic factors and health behaviours.Nationally representative cohort study.England, Scotland, and Wales.695 women followed-up since birth in 1946 and annually from age 47 to 54 who experienced (...) natural menopause and reported on 20 common health symptoms.Longitudinal profiles for reported bothersome symptoms.Of 20 individual symptoms, 18 formed into four stable symptom groups: psychological, somatic, vasomotor, and sexual discomfort. Using latent class analyses, all except the somatic group of symptoms showed a clear relation with the timing of menopause for some women. A small proportion of women (10%, n=63) had a severe psychological symptom profile that peaked at or in the year after

Full Text available with Trip Pro

2012 BMJ

138. Compounded Bioidentical Menopausal Hormone Therapy

Compounded Bioidentical Menopausal Hormone Therapy Compounded Bioidentical Menopausal Hormone Therapy - ACOG Menu ▼ Compounded Bioidentical Menopausal Hormone Therapy Page Navigation ▼ Number 532, August 2012 (Replaces No. 387, November 2007 and No. 322, November 2005) (Reaffirmed 2018) Committee on Gynecologic Practice and the American Society for Reproductive Medicine Practice Committee This document reflects emerging clinical and scientific advances as of the date issued and is subject (...) to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Compounded Bioidentical Menopausal Hormone Therapy ABSTRACT: Although improvement in long-term health is no longer an indication for menopausal hormone therapy, evidence supporting fewer adverse events in younger women, combined with its high overall effectiveness, has reinforced its usefulness for short-term treatment of menopausal symptoms. Menopausal therapy has been provided

2012 American College of Obstetricians and Gynecologists

139. Compounded bioidentical menopausal hormone therapy: a committee opinion

Compounded bioidentical menopausal hormone therapy: a committee opinion Compounded bioidentical menopausal hormone therapy American College of Obstetricians and Gynecologists Committee on Gynecologic Practice and American Society for Reproductive Medicine Practice Committee AmericanCollegeofObstetriciansandGynecologists, Washington, DC; andAmericanSocietyforReproductiveMedicine, Birmingham, Alabama Although improvement in long-term health is no longer an indication for menopausal hormone (...) marketingandmediapromotionofcompoundedbioidenticalhormonalpreparationsassafeandeffectivealternativestoconventional menopausal hormone therapy, have led to a recent increase in the popularity of compounded bioidentical hormones as well as an in- creaseinquestionsabouttheuseofthesepreparations.Notonlyisevidencelackingtosupportsuperiorityclaimsofcompoundedbio- identical hormones over conventional menopausal hormone therapy, but these claims also pose the additional risks ofvariable purity and potency and lack ef?cacy and safety data. The Committee on Gynecologic Practice of the American College

2012 Society for Assisted Reproductive Technology

140. Post-menopausal Hormone Treatment Update (DOPS, KEEPS)

Post-menopausal Hormone Treatment Update (DOPS, KEEPS) Post Post- -menopausal Hormonal Tx menopausal Hormonal Tx Is the pendulum swinging again? Is the pendulum swinging again? ? ? Pre Pre- -2002 2002 Nurses Health Study (observational) Nurses Health Study (observational) – – Hormones widely recommended for post Hormones widely recommended for post- -menopausal (PM) menopausal (PM) women; lots of potential benefit including women; lots of potential benefit including p p heart disease heart (...) ) ) – – PM hormones aren PM hormones aren’ ’t so bad after all, if used soon after t so bad after all, if used soon after menopausal onset, in younger women, for short time. In fact menopausal onset, in younger women, for short time. In fact one underpowered study says they may even be good. one underpowered study says they may even be good. Another, underpowered study suggests safety may be related Another, underpowered study suggests safety may be related to formulation used. Some reassured; others

2012 RxFiles